Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial (Q42646839)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial (English)

1 reference

Europe PubMed Central

4 November 2017

0 references

chronic heart failure

1 reference

based on heuristic

inferred from title

Dirk J van Veldhuisen

6

object named as

Dirk J van Veldhuisen

1 reference

Europe PubMed Central

4 November 2017

Adriaan A Voors

7

object named as

Adriaan A Voors

1 reference

Europe PubMed Central

4 November 2017

author name string

Suzan Willemsen

1

1 reference

Europe PubMed Central

4 November 2017

Jasper W L Hartog

2

1 reference

Europe PubMed Central

4 November 2017

Yoran M Hummel

3

1 reference

Europe PubMed Central

4 November 2017

Jan L Posma

4

1 reference

Europe PubMed Central

4 November 2017

Leen M van Wijk

5

1 reference

Europe PubMed Central

4 November 2017

publication date

25 January 2010

1 reference

Europe PubMed Central

4 November 2017

European Journal of Heart Failure

1 reference

Europe PubMed Central

4 November 2017

12

1 reference

Europe PubMed Central

4 November 2017

3

1 reference

Europe PubMed Central

4 November 2017

294-300

1 reference

Europe PubMed Central

4 November 2017

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Systolic and diastolic heart failure in the community.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Clinical and prognostic value of advanced glycation end-products in chronic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Simple noninvasive measurement of skin autofluorescence

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Recommendations for the evaluation of left ventricular diastolic function by echocardiography

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Stress testing methodology

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopath

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Heart failure with normal left ventricular ejection fraction: what is the evidence?

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Relation of exercise capacity to left ventricular systolic function and diastolic filling in idiopathic or ischemic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP207

21 January 2018

Identifiers

10.1093/EURJHF/HFP207

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42646839&oldid=1964420437"